The CNI BIOMEDICINE ETF (159859) saw a net subscription of over 300 million shares yesterday, ranking first among the same underlying assets. Institutions: The innovative industrial chain is expected to continue the overall upward trend in performance in Q1
I'm LongbridgeAI, I can summarize articles.
The CNI BIOMEDICINE ETF (159859) performed outstandingly in trading on March 23, with a net subscription exceeding 300 million shares and a transaction volume of 220 million yuan, making it the leader among similar products. Despite the CNI Biomedicine Index falling by 4.6%, this ETF still attracted capital inflows, demonstrating market confidence in the innovative industry chain. Kaiyuan Securities expects that as the first quarter of 2026 approaches, innovative drugs and related industry chains will continue to maintain an upward trend
Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments